INTRODUCTION
Type 2 diabetes mellitus currently constitutes an enormous global burden and annual prevalence rates continue to rise [1] . At present, an estimated 12% of the total health expenditure worldwide is directed towards this largely preventable disease [1] . Treatment of individuals with type 2 diabetes aims to achieve a normal lifespan and a quality of life (QOL) similar to that of persons without diabetes [2] . Long-term glycemic control is critical to prevent or delay the onset of macrovascular and microvascular complications and their associated consequences for patients' health and health-related QOL [2] .
Medication adherence is an integral component of type 2 diabetes management; however, treatment discontinuation during the early stages of the disease is not uncommon because patients are unaware of (or choose to ignore) their condition due to limited subjective symptoms or a low incidence of complications. Auto-recording systems for drug administration suggest that compliance difficulties increase with dosing frequency [3] . In this context, minimizing dosing frequency may increase treatment satisfaction and eliminate a major barrier to treatment continuation.
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a newer class of oral antidiabetic agent with longer-lasting glycemic control compared with conventional therapies [4] . These agents are increasingly being positioned higher in treatment algorithms for type 2 diabetes [5] . Several daily dosing DPP-4 inhibitors are available in Japan for administration once or twice daily [2] . The first weekly dosing DPP-4 inhibitor, trelagliptin, was launched in Japan in 2015.
Owing to its convenient once-weekly dosing schedule, trelagliptin has the potential to improve medication adherence, especially in patients newly starting oral glucose-lowering monotherapy [4] .
The availability of an antidiabetic medication with a reduced treatment burden may be conducive to patients continuing with treatment. Accordingly, this study has been proposed to assess treatment burden during treatment with weekly trelagliptin or a daily DPP-4 inhibitor in patients with type 2 diabetes beginning oral antidiabetic therapy.
The objective of the study is to evaluate the reduction in treatment burden during administration for 12 weeks of once-weekly trelagliptin compared with a daily DPP-4 inhibitor in Japanese patients with type 2 diabetes newly starting oral glucose-lowering monotherapy, by measuring their treatment-related QOL.
METHODS

Study Design
This is a multicenter, randomized, open-label, parallel-group, comparative study to be conducted at approximately 15 study sites across Japan. The study is registered at Japan Pharmaceutical Information Center Clinical Trials Information: Japic CTI-173482.
Inclusion Criteria
Study subject eligibility is to be determined in accordance with the following criteria: written informed consent prior to the initiation of any study procedures. 9. Patients aged C 20 years at the time of informed consent. Female subjects of childbearing potential will be required to use adequate contraception from the time of signing informed consent throughout the study period.
Exclusion Criteria
Study subjects meeting any of the following criteria will not be included in this study: Use of diabetic medications other than the allocated study medication is prohibited from the start of screening to the end of treatment. In principle, concomitant medications cannot be added or withdrawn or dosages changed during the clinical study period unless considered necessary by study investigators.
Study Procedure
The evaluation period is 16 weeks, consisting of a 4-week screening period and a 12-week treatment period (Fig. 1) . Subjects are to visit their corresponding study site four times during the course of the study: at the start of screening (visit 1, -4 weeks), at the start of treatment (visit 2, week 0), during treatment (visit 3, week 4), and at the end of treatment (visit 4, week 12). The 12-week study duration is considered to be an appropriate length of time to evaluate treatment response with oral antidiabetic medications [2] , and possibly also to evaluate changes in diabetes therapy-related QOL as patients become accustomed to treatment practice.
Assessments are to be performed according to the schedule for study procedures ( Table 1) . The investigator will observe and assess each participant from the time of informed consent through to treatment completion or discontinuation (until 14 days after the last dose of study medication). All examinations, observations, and evaluations are to be performed by the investigator at the designated time points.
Subjects' participation in the study may be discontinued at the investigator's discretion in the event of any of the following conditions: adverse event requiring withdrawal, major protocol deviation, loss to follow-up, voluntary withdrawal, study termination, pregnancy, lack of efficacy, or for any other reason which the investigator deems discontinuation to be necessary. Individual subjects may discontinue participation at any time during the study without providing a reason.
Efficacy Endpoints
The primary endpoint is the change in total score for all items (29 questions) of the DTR-QOL questionnaire from treatment start (week 0) to treatment end (week 12).
Secondary efficacy variables are: • Change in total score for each factor of the DTR-QOL questionnaire [factor 1: burden on social activities and daily activities (13 questions); factor 2: anxiety and dissatisfaction with treatment (8 questions); factor 3: hypoglycemia (4 questions); factor 4: treatment satisfaction (4 questions)] at each assessment time point.
• Change in total score for all questions of the DTR-QOL questionnaire at each assessment time point.
• Change in total score for items of the Diabetes Treatment Satisfaction questionnaire (DTSQ; 6 questions on treatment satisfaction, excepting 2 items for blood glucose control) [7, 8] at each assessment time point.
• Change in total score for all questions of the DTR-QOL questionnaire and all items of the DTSQ (for treatment satisfaction) stratified by the following factors at the start of treatment:
• Use of medication for treatment of comorbidities • Number of daily doses for treatment of comorbidities (\2 or C 2 times) • Total number of daily tablets for treatment of comorbidities (\2 or C 2 tablets) • Number of daily doses of study drug or comparative drug (once weekly, once daily, twice daily).
• Change in score for each question of the DTR-QOL questionnaire at each assessment time point.
• Change in score for each (treatment satisfaction) question of the DTSQ at each assessment time point.
Safety Endpoints
Safety is to be assessed according to adverse events, incidence of hypoglycemia, and duration and number of hospitalizations for type 2 diabetes, excluding hospitalizations for a type 2 diabetes education program.
Other Endpoints
Laboratory tests are to be performed under C 10 h fasting state conditions and in accordance with the schedule provided in Table 1 Fig. 2 .
Data Collection
Demographic data to be collected include date of birth, gender, height, weight, body mass index, smoking history, alcohol intake history, and time (month and year) of diabetes onset (or diabetes diagnosis).
Medical history is to include information on clinically problematic diseases and symptoms either resolved or recovered within a year before the start of the screening period.
Any continuous disease or symptom observed at screening until before the start of study treatment will be regarded as a comorbidity.
Physical Examination
The presence/absence of clinically significant abnormalities at subsequent physical examinations during the course of treatment will be determined by comparison with the baseline physical examination.
Concomitant Medication
Use of concomitant medications (name, dosage, route of administration, duration, intended use), either prescribed by physicians or over-the-counter medicines purchased by study subjects, will be investigated and recorded at each visit from start of screening to study completion. Also recorded will be: use of therapeutic drugs for comorbidities; number of daily doses of drugs, including therapeutic drugs for comorbidities (\2 times or C 2 times); and total number of daily tablets of drugs, including therapeutic drugs for comorbidities (\2 tablets or C 2 tablets), from the start of screening to study completion.
Adverse Events
Adverse events, including adverse events of special interest to DPP-4 inhibitors as per product labels, are to be collected from the start of treatment to the end of the treatment period (or discontinuation). Any adverse event will be assessed with respect to its name, seriousness, severity, causal relationship to study medication, causal relationship with study procedures, date of onset, date of resolution, actions taken, and outcome.
Adverse events, medical history, and comorbidities will be coded using the Medical Dictionary for Regulatory Activities (MedDRA).
Treatment Adherence
Subjects are to be instructed to record study drug or comparative drug usage on a Diabetes Treatment Medication Record Card by pressing a button at the time the medication is taken. The card's electronic circuit board will record the time(s) of day that the medication is taken. Subjects will be instructed to bring any leftover medication and empty sheets at each visit to allow adherence and usage to be checked along with the Diabetes Treatment Medication Record Card.
Statistical Methods
Two analysis sets have been defined for the study. The full analysis set (FAS) includes all randomized subjects who receive at least one dose of trelagliptin or a daily DPP-4 inhibitor. The safety population includes subjects who receive at least one dose of trelagliptin or a daily DPP-4 inhibitor.
Efficacy endpoints will be analyzed in the FAS. For the primary endpoint, comparison between treatment groups is to be conducted using the analysis of covariance (ANCOVA) model, including: change in total score for all items of the DTR-QOL questionnaire from treatment start to treatment end (week 0 to week 12) as a dependent variable; total score of the DTR-QOL questionnaire (\80 or C 80) and HbA1c (\8.0% or C 8.0%) at the start of the screening period as covariates; treatment group as an independent variable. The level of significance is 5% (two-sided).
For the secondary endpoints of change in total score for each factor of the DTR-QOL How often did you forget to take your medication(s) for conditions other than diabetes (e.g. hypertension) for the past one month?
How often did you forget to take your diabetes medication(s) for the past one month?
How often did you have to take your medication(s) during your busy hours for the past one month?
Your Basic Profile VISIT3
Please answer the following questions by circling the applicable number for each question. Please answer how you felt when you were in the following situaƟons for the past one month, by circling the number which best represents your feeling for each quesƟon.
I felt guilty when I forgot to take my diabetes medication(s).
It is burdensome to take my diabetes medication(s) when I'm going out, travelling, or on a business trip. 
3)
At
4)
5)
Always Sometimes Occasionally Rarely Never Please answer how you felt when you were in the following situations for the past one month, by circling the number which best represents your feeling for each question.
I felt guilty when I forgot to take my diabetes medication(s).
It is burdensome to take my diabetes medication(s) when I'm going out, travelling, or on a business trip.
Which type of medication would you like to use to treat your diabetes assuming that benefits, side effects and daily costs are the same?
Your Basic Profile VISIT4 Fig. 2 continued questionnaire at each assessment time point, change in total score for all questions of the DTR-QOL questionnaire at each assessment time point, and change in total score for all (treatment satisfaction) questions of the DTSQ at each assessment time point, summary statistics [number of patients, mean, standard deviation (SD), maximum, minimum, and quantile] and two-sided 95% confidence intervals (CIs) for means per treatment group will be calculated to plot changes in means and SDs. Point estimates and two-sided 95% CIs for differences between treatment groups will also be calculated. This same analysis will be performed for the change in mean from baseline (week 0) of each secondary efficacy variable. The ANCOVA model described above for the primary endpoint will also be used to analyze total scores for each factor of the DTR-QOL questionnaire and the DTSQ.
With regard to other endpoints, summary statistics for measurements or changes from baseline (week 0) in laboratory tests will be calculated per treatment group. The treatment adherence of each study subject will be calculated and summary statistics per treatment group will be analyzed. Frequency of answers to each question of Your Basic Profile at each visit will be calculated and summary statistics per treatment group will be analyzed.
Safety endpoints will be analyzed in the safety population using frequency tables for incidences of adverse events, hypoglycemia, and hospitalizations for worsening type 2 diabetes per treatment group.
Rationale for Planned Sample Size
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